Understanding the GP Data Extraction Scheme & Use of Patient Data

The General Practice Data for Planning and Research (GPDPR) is a proposed central NHS digital database collating patient data from GP records in England. Originally 1 July 2021, the date for launch has been pushed back to 1 September after...

3 days ago
Clinical Development,Clinical Operations,Data,News

Understanding the GP Data Extraction Scheme & Use of Patient Data

The General Practice Data for Planning and Research (GPDPR) is a proposed central NHS digital database collating patient data from GP records in England. Originally 1 July 2021, the date for launch has been pushed back to 1 September after...

3 days ago

Another Direction for Clinical Oncology: Targeting the Anti-Inflammatory Response in Cancer

Approximately 15-20% of all cancer cases are preceded by infection, chronic inflammation, or autoimmunity at the same tissue or organ site. While inflammation is a natural response to tissue damage, chronic inflammation can become pathological. The role of inflammation in...

5 days ago
Oncology,Biology,News

Another Direction for Clinical Oncology: Targeting the Anti-Inflammatory Response in Cancer

Approximately 15-20% of all cancer cases are preceded by infection, chronic inflammation, or autoimmunity at the same tissue or organ site. While inflammation is a natural response to tissue damage, chronic inflammation can become pathological. The role of inflammation in...

5 days ago

Targeted Protein Degradation: A Potential Tool for Discovering Druggable Targets

Drug discovery is the first step in therapeutic breakthroughs. Unfortunately, this cannot occur without target discovery - the identification and validation of druggable targets. Whether it be proteins or small molecules, discovering a ‘druggable’ biological target can be a challenge...

6 days ago
R&D,Biology,News

Targeted Protein Degradation: A Potential Tool for Discovering Druggable Targets

Drug discovery is the first step in therapeutic breakthroughs. Unfortunately, this cannot occur without target discovery - the identification and validation of druggable targets. Whether it be proteins or small molecules, discovering a ‘druggable’ biological target can be a challenge...

6 days ago

Biobanks and EHR Data in Drug Design and Development

Over the last five years, drug design and development has evolved substantially with technological innovations. Electronic health records (EHRs) have played an important role in utilising health data on a digital platform in both preclinical and clinical studies. Biobanks have...

7 days ago
R&D,Biology,News

Biobanks and EHR Data in Drug Design and Development

Over the last five years, drug design and development has evolved substantially with technological innovations. Electronic health records (EHRs) have played an important role in utilising health data on a digital platform in both preclinical and clinical studies. Biobanks have...

7 days ago

How Has The Covid-19 Pandemic Impacted Oncology and Clinical Operations?

As a part of Proventa’s Clinical Operations and Oncology Meeting May 2021, we organised a number of interesting keynote sessions pondering the latest innovations, challenges and strategies for the future. The morning keynote, hosted by Tanya Russel Kirkpatrick, VP Clinical...

7 days ago
Oncology,Clinical Operations,Biology,News

How Has The Covid-19 Pandemic Impacted Oncology and Clinical Operations?

As a part of Proventa’s Clinical Operations and Oncology Meeting May 2021, we organised a number of interesting keynote sessions pondering the latest innovations, challenges and strategies for the future. The morning keynote, hosted by Tanya Russel Kirkpatrick, VP Clinical...

7 days ago

AstraZeneca/Alexion Purchase Held Up by CMA Amid Concerns

In December 2020, pharma giant AstraZeneca (AZ) announced its intention to acquire biopharmaceutical company Alexion. The merger would give AZ an increased portfolio in rare disease and immunology. While the US Federal Trade Commission (FTC) has approved the merger, several...

1 week ago
Investment,Biology,News

AstraZeneca/Alexion Purchase Held Up by CMA Amid Concerns

In December 2020, pharma giant AstraZeneca (AZ) announced its intention to acquire biopharmaceutical company Alexion. The merger would give AZ an increased portfolio in rare disease and immunology. While the US Federal Trade Commission (FTC) has approved the merger, several...

1 week ago

The Great Debate: The Utilisation of True AI in All Aspects of Drug Discovery

As a part of Proventa’s Medicinal Chemistry and Biology Strategy Meeting May 2021, we organised a number of interesting keynote sessions pondering the latest innovations, challenges and strategies for the future. The morning keynote, hosted by Gilead’s Executive Director for...

2 weeks ago
R&D,Biology,News

The Great Debate: The Utilisation of True AI in All Aspects of Drug Discovery

As a part of Proventa’s Medicinal Chemistry and Biology Strategy Meeting May 2021, we organised a number of interesting keynote sessions pondering the latest innovations, challenges and strategies for the future. The morning keynote, hosted by Gilead’s Executive Director for...

2 weeks ago

Biomarker Discovery and Validation: Current Challenges in Oncology

Biomarkers have shown significant potential across oncology clinical studies, especially in precision medicine for immunotherapy. Therefore, it is important that biomarker discovery and validation is optimised to produce the most effective drugs for patient populations. False positives and experimental bias...

2 weeks ago
Oncology,R&D,Biology,News

Biomarker Discovery and Validation: Current Challenges in Oncology

Biomarkers have shown significant potential across oncology clinical studies, especially in precision medicine for immunotherapy. Therefore, it is important that biomarker discovery and validation is optimised to produce the most effective drugs for patient populations. False positives and experimental bias...

2 weeks ago

First Potential Alzheimer’s Drug on the Brink of FDA Approval

On 7 June 2021, Biogen will receive an answer from the FDA regarding the approval of their Alzheimer’s drug, Aducanumab. Approval for this drug will represent a significant milestone in disease management for Alzheimer’s patients, in terms of slowing the...

2 weeks ago
R&D,Clinical Development,Biology,News

First Potential Alzheimer’s Drug on the Brink of FDA Approval

On 7 June 2021, Biogen will receive an answer from the FDA regarding the approval of their Alzheimer’s drug, Aducanumab. Approval for this drug will represent a significant milestone in disease management for Alzheimer’s patients, in terms of slowing the...

2 weeks ago

Supporting Diversity in Clinical Trials: An Interview with Ash Rishi, COUCH Health

COVID-19 has changed how many sponsors enrol and retain trial participants. From decentralisation, increased use of wearables and changes in population targeting, the pandemic has seen a shift in both priorities and procedures with regard to enrolment. But is this...

2 weeks ago
Clinical Operations,Race and Ethics,Precision and Personalised Medicine,Biology,News

Supporting Diversity in Clinical Trials: An Interview with Ash Rishi, COUCH Health

COVID-19 has changed how many sponsors enrol and retain trial participants. From decentralisation, increased use of wearables and changes in population targeting, the pandemic has seen a shift in both priorities and procedures with regard to enrolment. But is this...

2 weeks ago